These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 30406361)

  • 1. Phase I/IIa PET imaging study with
    Joraku A; Hatano K; Kawai K; Kandori S; Kojima T; Fukumitsu N; Isobe T; Mori Y; Sakata M; Hara T; Nasu K; Minami M; Iizumi Y; Nishiyama H
    Ann Nucl Med; 2019 Feb; 33(2):119-127. PubMed ID: 30406361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake.
    Pandit-Taskar N; O'Donoghue JA; Ruan S; Lyashchenko SK; Carrasquillo JA; Heller G; Martinez DF; Cheal SM; Lewis JS; Fleisher M; Keppler JS; Reiter RE; Wu AM; Weber WA; Scher HI; Larson SM; Morris MJ
    J Nucl Med; 2016 Dec; 57(12):1858-1864. PubMed ID: 27516450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential use of prostate specific membrane antigen (PSMA) for detecting the tumor neovasculature of brain tumors by PET imaging with
    Matsuda M; Ishikawa E; Yamamoto T; Hatano K; Joraku A; Iizumi Y; Masuda Y; Nishiyama H; Matsumura A
    J Neurooncol; 2018 Jul; 138(3):581-589. PubMed ID: 29524126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pilot study of the diagnostic utility of
    Vlachostergios PJ; Niaz MJ; Thomas C; Christos PJ; Osborne JR; Margolis DJA; Khani F; Bander NH; Scherr DS; Tagawa ST
    Prostate; 2022 Mar; 82(4):483-492. PubMed ID: 34985786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imaging with [
    Tendler S; Dunphy MP; Agee M; O'Donoghue J; Aly RG; Choudhury NJ; Kesner A; Kirov A; Mauguen A; Baine MK; Schoder H; Weber WA; Rekhtman N; Lyashchenko SK; Bodei L; Morris MJ; Lewis JS; Rudin CM; Poirier JT
    Lancet Oncol; 2024 Aug; 25(8):1015-1024. PubMed ID: 38950555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiation dosimetry of 89Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients.
    Börjesson PK; Jauw YW; de Bree R; Roos JC; Castelijns JA; Leemans CR; van Dongen GA; Boellaard R
    J Nucl Med; 2009 Nov; 50(11):1828-36. PubMed ID: 19837762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-in-Humans Imaging with
    Pandit-Taskar N; Postow MA; Hellmann MD; Harding JJ; Barker CA; O'Donoghue JA; Ziolkowska M; Ruan S; Lyashchenko SK; Tsai F; Farwell M; Mitchell TC; Korn R; Le W; Lewis JS; Weber WA; Behera D; Wilson I; Gordon M; Wu AM; Wolchok JD
    J Nucl Med; 2020 Apr; 61(4):512-519. PubMed ID: 31586002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ⁸⁹Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer.
    Pandit-Taskar N; O'Donoghue JA; Beylergil V; Lyashchenko S; Ruan S; Solomon SB; Durack JC; Carrasquillo JA; Lefkowitz RA; Gonen M; Lewis JS; Holland JP; Cheal SM; Reuter VE; Osborne JR; Loda MF; Smith-Jones PM; Weber WA; Bander NH; Scher HI; Morris MJ; Larson SM
    Eur J Nucl Med Mol Imaging; 2014 Nov; 41(11):2093-105. PubMed ID: 25143071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD8-Targeted PET Imaging of Tumor-Infiltrating T Cells in Patients with Cancer: A Phase I First-in-Humans Study of
    Farwell MD; Gamache RF; Babazada H; Hellmann MD; Harding JJ; Korn R; Mascioni A; Le W; Wilson I; Gordon MS; Wu AM; Ulaner GA; Wolchok JD; Postow MA; Pandit-Taskar N
    J Nucl Med; 2022 May; 63(5):720-726. PubMed ID: 34413145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of PET/CT imaging with [89Zr]Zr-DFO-girentuximab: a phase 1 clinical study in Japanese patients with renal cell carcinoma (Zirdac-JP).
    Nakaigawa N; Hasumi H; Utsunomiya D; Yoshida K; Ishiwata Y; Oka T; Hayward C; Makiyama K
    Jpn J Clin Oncol; 2024 Aug; 54(8):873-879. PubMed ID: 38864246
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Schwenck J; Sonanini D; Seyfried D; Ehrlichmann W; Kienzle G; Reischl G; Krezer P; Wilson I; Korn R; Gonzalez-Menendez I; Quintanilla-Martinez L; Seith F; Forschner A; Eigentler T; Zender L; Röcken M; Pichler BJ; Flatz L; Kneilling M; la Fougere C
    Theranostics; 2023; 13(8):2408-2423. PubMed ID: 37215571
    [No Abstract]   [Full Text] [Related]  

  • 12. Performance of immuno-positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients.
    Börjesson PK; Jauw YW; Boellaard R; de Bree R; Comans EF; Roos JC; Castelijns JA; Vosjan MJ; Kummer JA; Leemans CR; Lammertsma AA; van Dongen GA
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2133-40. PubMed ID: 16609026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ⁸⁹Zr-Labeled Versus ¹²⁴I-Labeled αHER2 Fab with Optimized Plasma Half-Life for High-Contrast Tumor Imaging In Vivo.
    Mendler CT; Gehring T; Wester HJ; Schwaiger M; Skerra A
    J Nucl Med; 2015 Jul; 56(7):1112-8. PubMed ID: 25999431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-in-human imaging with [
    Tendler S; Dunphy MP; Agee M; O'Donoghue J; Aly RG; Choudhury NJ; Kesner A; Kirov A; Mauguen A; Baine MK; Schoder H; Weber WA; Rekhtman N; Lyashchenko SK; Bodei L; Morris MJ; Lewis JS; Rudin CM; Poirier JT
    medRxiv; 2024 Jan; ():. PubMed ID: 38260492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [
    Zettlitz KA; Tsai WK; Knowles SM; Salazar FB; Kobayashi N; Reiter RE; Wu AM
    Mol Imaging Biol; 2020 Apr; 22(2):367-376. PubMed ID: 31209779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and Biodistribution of a [
    O'Donoghue JA; Danila DC; Pandit-Taskar N; Beylergil V; Cheal SM; Fleming SE; Fox JJ; Ruan S; Zanzonico PB; Ragupathi G; Lyashchenko SK; Williams SP; Scher HI; Fine BM; Humm JL; Larson SM; Morris MJ; Carrasquillo JA
    Mol Pharm; 2019 Jul; 16(7):3083-3090. PubMed ID: 31117485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative immunoPET of prostate cancer xenografts with 89Zr- and 124I-labeled anti-PSCA A11 minibody.
    Knowles SM; Zettlitz KA; Tavaré R; Rochefort MM; Salazar FB; Stout DB; Yazaki PJ; Reiter RE; Wu AM
    J Nucl Med; 2014 Mar; 55(3):452-9. PubMed ID: 24504052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pharmacokinetics of Zr-89 labeled liposomes over extended periods in a murine tumor model.
    Seo JW; Mahakian LM; Tam S; Qin S; Ingham ES; Meares CF; Ferrara KW
    Nucl Med Biol; 2015 Feb; 42(2):155-63. PubMed ID: 25451215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Positron emission tomography imaging of CD105 expression with 89Zr-Df-TRC105.
    Hong H; Severin GW; Yang Y; Engle JW; Zhang Y; Barnhart TE; Liu G; Leigh BR; Nickles RJ; Cai W
    Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):138-48. PubMed ID: 21909753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study to assess safety, biodistribution and radiation dosimetry for
    Merkx RIJ; Lobeek D; Konijnenberg M; Jiménez-Franco LD; Kluge A; Oosterwijk E; Mulders PFA; Rijpkema M
    Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3277-3285. PubMed ID: 33651116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.